分子诊断与[18F]FDG-PET/CT在意义不明确的甲状腺结节中的应用:互补技术还是浪费宝贵资源?
这项前瞻性多中心研究纳入132例Bethesda III或IV甲状腺结节患者,评估分子诊断(MD)与[18F]FDG-PET/CT单独及联合使用的效能。MD的灵敏度、特异度、NPV、PPV和良性呼叫率分别为80%、69%、91%、48%和57%,PET/CT分别为93%、41%、95%、36%和32%。作者认为两者均为准确的排除性检查,但联合使用的获益在考虑治疗后果时可能有限,不应常规推荐。
要点
- MD在115/132例(87%)中获得诊断结果,灵敏度80%、特异度69%、NPV 91%。
- [18F]FDG-PET/CT灵敏度93%、特异度41%、NPV 95%,良性呼叫率32%。
- 双阴性联合检测灵敏度95%、特异度44%;双阳性联合检测灵敏度68%、特异度86%。
核心结论
- MD与[18F]FDG-PET/CT均为准确的排除性检查,前提是未切除且超声随访无变化的结节被视为良性。
- 两者虽互补,但考虑治疗后果时联合使用的获益可能有限,因此不应常规推荐。
- 在非嗜酸细胞性意义不明确的甲状腺结节中,若第一步MD阴性,可考虑序贯检测以确认暂不手术在肿瘤学上是安全的。
- 在嗜酸细胞性意义不明确的甲状腺结节中,经进一步验证研究后,可考虑MD。
研究设计与样本
- 前瞻性多中心研究,纳入成年、甲状腺功能正常、Bethesda III或IV甲状腺结节患者。
- 所有患者均接受MD和颈部[18F]FDG-PET/CT检查。
- MD采用定制二代测序面板检测体细胞突变、基因融合、拷贝数改变及杂合性缺失。
- 共纳入132例患者,其中115例(87%)MD在细胞学上获得诊断结果。
- 临床试验注册号NCT02208544,注册日期2014年8月5日。
主要发现
- MD的灵敏度80%、特异度69%、NPV 91%、PPV 48%、良性呼叫率57%。
- [18F]FDG-PET/CT的灵敏度93%、特异度41%、NPV 95%、PPV 36%、良性呼叫率32%。
- 双阴性联合检测(MD阴性加PET/CT阴性)灵敏度95%、特异度44%;双阳性联合检测灵敏度68%、特异度86%。
- MD与[18F]FDG-PET/CT的一致率为63%(82/130)。
- [18F]FDG阳性良性结节中MD阳性者25/59(42%),包括11例(44%)孤立RAS突变;[18F]FDG阴性良性结节中MD阳性者7/30(19%),p=0.02。
关键数值与推荐
- MD:灵敏度80%、特异度69%、NPV 91%、PPV 48%、良性呼叫率57%。
- [18F]FDG-PET/CT:灵敏度93%、特异度41%、NPV 95%、PPV 36%、良性呼叫率32%。
- 双阴性联合检测:灵敏度95%、特异度44%;双阳性联合检测:灵敏度68%、特异度86%。
- MD与[18F]FDG-PET/CT一致率63%(82/130)。
- [18F]FDG阳性良性结节中MD阳性25/59(42%),[18F]FDG阴性良性结节中MD阳性7/30(19%),p=0.02。
临床怎么用
- 作者认为,MD与[18F]FDG-PET/CT均为准确的排除性检查,但联合使用不应常规推荐。
- 作者建议,在非嗜酸细胞性意义不明确的甲状腺结节中,若第一步MD阴性,可考虑序贯检测以确认暂不手术在肿瘤学上是安全的。
- 作者认为,在嗜酸细胞性意义不明确的甲状腺结节中,经进一步验证研究后,可考虑MD。
- 作者指出,哪种检查最合适可能因全球各地诊断可及性、专业知识和成本效益考虑而异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: An accurate preoperative workup of cytologically indeterminate thyroid nodules (ITN) may rule out malignancy and avoid diagnostic surgery for benign nodules. This study assessed the performance of molecular diagnostics (MD) and 2-[18F]fluoro-2-deoxy-d-glucose ([18F]FDG)-positron emission tomography/computed tomography (PET/CT) in ITN, including their combined use, and explored whether molecular alterations drive the differences in [18F]FDG uptake among benign nodules. Methods: Adult, euthyroid patients with a Bethesda III or IV thyroid nodule were prospectively included in this multicenter study. They all underwent MD and an [18F]FDG-PET/CT scan of the neck. MD was performed using custom next-generation sequencing panels for somatic mutations, gene fusions, and copy number alterations and loss of heterozygosity. Sensitivity, specificity, negative and positive predictive value (NPV, PPV), and benign call rate (BCR) were assessed for MD and [18F]FDG-PET/CT separately and for a combined approach using both techniques. Results: In 115 of the 132 (87%) included patients, MD yielded a diagnostic result on cytology. Sensitivity, specificity, NPV, PPV, and BCR were 80%, 69%, 91%, 48%, and 57% for MD, and 93%, 41%, 95%, 36%, and 32% for [18F]FDG-PET/CT, respectively. When combined, sensitivity and specificity were 95% and 44% for a double-negative test (i.e., negative MD plus negative [18F]FDG-PET/CT) and 68% and 86% for a double-positive test, respectively. Concordance was 63% (82/130) between MD and [18F]FDG-PET/CT. There were more MD-positive nodules among the [18F]FDG-positive benign nodules (25/59, 42%, including 11 (44%) isolated RAS mutations) than among the [18F]FDG-negative benign nodules (7/30, 19%, p = 0.02). In oncocytic ITN, the BCR of [18F]FDG-PET/CT was mere 3% and MD was the superior technique. Conclusions: MD and [18F]FDG-PET/CT are both accurate rule-out tests when unresected nodules that remain unchanged on ultrasound follow-up are considered benign. It may vary worldwide which test is considered most suitable, depending on local availability of diagnostics, expertise, and cost-effectiveness considerations. Although complementary, the benefits of their combined use may be confined when therapeutic consequences are considered, and should therefore not routinely be recommended. In nononcocytic ITN, sequential testing may be considered in case of a first-step MD negative test to confirm that withholding diagnostic surgery is oncologically safe. In oncocytic ITN, after further validation studies, MD might be considered. Clinical Trial Registration: This trial is registered with ClinicalTrials.gov: NCT02208544 (August 5, 2014), https://clinicaltrials.gov/ct2/show/NCT02208544.
引用
- de Koster EJ, Morreau H, Bleumink GS, et al. Molecular Diagnostics and [18F]FDG-PET/CT in Indeterminate Thyroid Nodules: Complementing Techniques or Waste of Valuable Resources? Thyroid. 2023. PMID: 38009209. doi:10.1089/thy.2023.0337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。